Sheena Chand
Medical · Longmont, CONPI 1871739847
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,124 of the $7,144 with a category attached, or 85.7%. It is spread thinly across 26 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,395 and has fallen 63.7% since, to $869 in 2025. Among medical clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $33.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- LEO Pharma Inc.$998
- Amgen$633
- UCB, Inc.$621
- Novartis$517
- Johnson & Johnson$433
- plus $3K from 20 others
What the payments were for
- Consulting fees$6759%
- Speaking & faculty fees$451%
- Food & beverage$6,12486%
- Education$3004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $1,076 |
| LEO Pharma Inc. | 11 | $998 |
| Amgen | 30 | $633 |
| UCB, Inc. | 13 | $621 |
| Novartis | 15 | $517 |
| Johnson & Johnson | 13 | $433 |
| Sun Pharmaceutical Industries Inc. | 11 | $412 |
| Sanofi | 15 | $407 |
| Arcutis Biotherapeutics, Inc. | 8 | $308 |
| Galderma Laboratories, L.p. | 10 | $247 |
| E.r. Squibb & Sons, L.L.C. | 6 | $230 |
| Lilly USA, LLC | 10 | $202 |
| Almirall LLC | 3 | $186 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 8 | $173 |
| Pfizer | 8 | $144 |
| Incyte Corporation | 4 | $142 |
| Regeneron Healthcare Solutions, Inc. | 4 | $106 |
| Organon | 2 | $82 |
| Journey Medical Corporation | 4 | $73 |
| Boston Scientific | 1 | $41 |
| Krystal Biotech Inc | 1 | $34 |
| Dermira, Inc. | 1 | $20 |
| Organogenesis Inc. | 1 | $16 |
| VYNE Pharmaceuticals Inc. | 1 | $16 |
| Dermavant Sciences, Inc. | 1 | $14 |
| Kerecis Limited | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,144 in reported general payments places this provider in the 90th percentile of 766 medical providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 16 | $59,339 |
| AdbryTralokinumab-Ldrm | 12 | $45,217 |
| Fluorouracil | 24 | $1,951 |
| Clobetasol Propionate | 25 | $1,468 |
| Doxycycline Hyclate | 33 | $783 |
| Metronidazole | 12 | $703 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 21 | $684 |
| Ketoconazole | 16 | $234 |
| ValacyclovirValacyclovir Hcl | 17 | $230 |
| Triamcinolone Acetonide | 21 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| LEO Pharma Inc.Adbry | $998 | $45,21712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 766 medical providers in Colorado.
Other medical in Longmont
- Christen KutzColorado Springs$610K
- Amanda MixonFort Collins$342K
- Kristin RyggColorado Springs$255K
- Jordan MastDenver$247K
- John NovakAurora$173K
- Michelle BarnettColorado Springs$138K
- Michael JacobsonFort Collins$131K
- Lindsey TunstallAurora$87K
- Jennifer NafzigerHighlands Ranch$80K
- Daniel TaylorDenver$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.